newsfilter
← Latest News
Business Wire·

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Lower doses of ANEB-001 reduced the negative effects of higher doses of THC Currently exploring delayed dosing to better understand real-world conditions Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company